[go: up one dir, main page]

HUS1900047I1 - Liofilizált liposzómák - Google Patents

Liofilizált liposzómák

Info

Publication number
HUS1900047I1
HUS1900047I1 HUS1900047C HUS1900047I1 HU S1900047 I1 HUS1900047 I1 HU S1900047I1 HU S1900047 C HUS1900047 C HU S1900047C HU S1900047 I1 HUS1900047 I1 HU S1900047I1
Authority
HU
Hungary
Prior art keywords
lyophilized liposomes
liposomes
lyophilized
Prior art date
Application number
Other languages
English (en)
Original Assignee
Jazz Pharmaceuticals Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1900047(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Res Llc filed Critical Jazz Pharmaceuticals Res Llc
Publication of HUS1900047I1 publication Critical patent/HUS1900047I1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
HUS1900047 2011-10-21 2019-10-10 Liofilizált liposzómák HUS1900047I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
EP12841616.1A EP2768484B1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Publications (1)

Publication Number Publication Date
HUS1900047I1 true HUS1900047I1 (hu) 2019-11-28

Family

ID=48141268

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE12841616A HUE045978T2 (hu) 2011-10-21 2012-10-15 Liofilizált liposzómák
HUS1900047 HUS1900047I1 (hu) 2011-10-21 2019-10-10 Liofilizált liposzómák

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE12841616A HUE045978T2 (hu) 2011-10-21 2012-10-15 Liofilizált liposzómák

Country Status (22)

Country Link
US (5) US10028912B2 (hu)
EP (2) EP3572071A1 (hu)
JP (6) JP6133308B2 (hu)
KR (5) KR102113753B1 (hu)
CN (2) CN104114156A (hu)
AU (1) AU2012326370C9 (hu)
BR (1) BR112014009305B1 (hu)
CA (1) CA2852777C (hu)
DK (1) DK2768484T3 (hu)
ES (1) ES2750368T3 (hu)
FR (1) FR19C1063I2 (hu)
HR (1) HRP20191683T1 (hu)
HU (2) HUE045978T2 (hu)
IL (1) IL232161B (hu)
LU (1) LUC00135I2 (hu)
NL (1) NL301016I2 (hu)
NO (1) NO2019041I1 (hu)
PL (1) PL2768484T3 (hu)
PT (1) PT2768484T (hu)
RU (1) RU2648753C2 (hu)
SI (1) SI2768484T1 (hu)
WO (1) WO2013059133A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2768484T3 (da) * 2011-10-21 2019-10-07 Jazz Pharmaceuticals Res Llc Lyofiliserede liposomer
BR112016003084A2 (pt) 2013-08-13 2017-09-12 Univ Northwestern partículas conjugadas com peptídeo
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
AU2015308794A1 (en) 2014-08-28 2017-03-02 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
EP3283045B1 (en) * 2015-04-13 2021-02-17 Fountain Technologies International, LLC One-step method for production of ultra-small lipid structures
DK3324932T3 (da) 2015-07-22 2021-04-06 Nitto Denko Corp Sammensætninger og fremgangsmåder for nanopartikel lyofile former
AU2016353163B2 (en) 2015-11-11 2022-09-29 Jazz Pharmaceuticals Therapeutics, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
WO2017147367A1 (en) 2016-02-26 2017-08-31 The General Hospital Corporation Medical ice slurry production and delivery systems and methods
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3069019A1 (en) * 2017-07-10 2019-01-17 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
BR112021005539A2 (pt) 2018-09-25 2021-06-29 Celator Pharmaceuticals, Inc. tratamento de baixa intensidade de transtornos hematológicos
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
KR20220027941A (ko) * 2019-06-28 2022-03-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 리포솜 아나마이신의 재구성 방법
US20220273569A1 (en) * 2019-07-24 2022-09-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术(石家庄)有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
JPS62501631A (ja) * 1985-01-11 1987-07-02 ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア リポソ−ムの保持法
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
ATE237362T1 (de) * 1996-02-19 2003-05-15 Amersham Health As Thermostabilisiertes kontrastmittel
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
HK1047046B (zh) 1999-07-16 2005-06-03 阿尔萨公司 抗冻/融损害的脂质体组合物
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7238367B2 (en) 2001-10-03 2007-07-03 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
ATE373466T1 (de) 2001-11-13 2007-10-15 Celator Pharmaceuticals Inc Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
PT1443900E (pt) 2001-11-13 2012-08-01 Celator Pharmaceuticals Inc Composições de veículo lipídico com estabilidade melhorada no sangue
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
CA2536612A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination compositions of camptothecins and fluoropyrimidines
CA2564542C (en) 2004-04-22 2012-11-27 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
US7893338B2 (en) 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
JP4990786B2 (ja) * 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
CA2587741A1 (en) 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
DK3300601T3 (da) * 2007-02-16 2022-03-21 Rotalec Ip Holdings Llc Faste lægemiddelforhold til behandling af hæmatopoietiske kræftformer og proliferative lidelser
US20120003294A1 (en) 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
WO2009070761A1 (en) 2007-11-28 2009-06-04 Celator Pharmaceuticals, Inc Improved taxane delivery system
WO2010043050A1 (en) 2008-10-16 2010-04-22 Celator Pharmaceuticals Corporation Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
ES2547698T3 (es) 2009-12-03 2015-10-08 Jiangsu Hengrui Medicine Co., Ltd. Liposoma de irinotecán o su clorhidrato y método de preparación del mismo
US20130052259A1 (en) 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
DK2768484T3 (da) * 2011-10-21 2019-10-07 Jazz Pharmaceuticals Res Llc Lyofiliserede liposomer

Also Published As

Publication number Publication date
KR20220141906A (ko) 2022-10-20
RU2648753C2 (ru) 2018-03-28
PT2768484T (pt) 2019-10-28
JP7476161B2 (ja) 2024-04-30
US10028912B2 (en) 2018-07-24
KR102113753B1 (ko) 2020-05-21
AU2012326370C1 (en) 2023-03-30
LUC00135I1 (hu) 2019-10-25
RU2018107407A (ru) 2019-02-25
NL301016I2 (nl) 2020-04-16
CA2852777C (en) 2020-10-27
JP2020007367A (ja) 2020-01-16
US20210169803A1 (en) 2021-06-10
JP6133308B2 (ja) 2017-05-24
NO2019041I1 (no) 2019-11-25
NL301016I1 (nl) 2019-10-30
US20190070112A1 (en) 2019-03-07
IL232161B (en) 2019-07-31
KR20210095746A (ko) 2021-08-02
EP2768484A4 (en) 2015-04-22
FR19C1063I1 (fr) 2019-11-22
HK1201039A1 (en) 2015-08-21
SI2768484T1 (sl) 2019-12-31
EP2768484A1 (en) 2014-08-27
JP2014532623A (ja) 2014-12-08
IL232161A0 (en) 2014-05-28
KR20190111139A (ko) 2019-10-01
CN108853031A (zh) 2018-11-23
HRP20191683T1 (hr) 2019-12-13
KR102284689B1 (ko) 2021-08-02
JP6359717B2 (ja) 2018-07-18
US10835492B2 (en) 2020-11-17
CN104114156A (zh) 2014-10-22
JP2022033892A (ja) 2022-03-02
EP3572071A1 (en) 2019-11-27
WO2013059133A1 (en) 2013-04-25
US20180161273A1 (en) 2018-06-14
AU2012326370B2 (en) 2017-06-01
KR102024836B1 (ko) 2019-09-24
LUC00135I2 (hu) 2021-02-12
KR102452305B1 (ko) 2022-10-07
FR19C1063I2 (fr) 2020-10-30
US20140255475A1 (en) 2014-09-11
KR20200057104A (ko) 2020-05-25
JP6592556B2 (ja) 2019-10-16
HUE045978T2 (hu) 2020-01-28
ES2750368T3 (es) 2020-03-25
EP2768484B1 (en) 2019-07-24
JP2017160211A (ja) 2017-09-14
PL2768484T3 (pl) 2019-12-31
BR112014009305B1 (pt) 2023-01-24
BR112014009305A2 (pt) 2017-04-11
DK2768484T3 (da) 2019-10-07
AU2012326370C9 (en) 2023-05-18
US10166184B2 (en) 2019-01-01
AU2012326370A2 (en) 2014-06-12
KR20140092323A (ko) 2014-07-23
JP2018150342A (ja) 2018-09-27
RU2014120475A (ru) 2015-11-27
RU2018107407A3 (hu) 2021-05-04
CA2852777A1 (en) 2013-04-25
JP2024045183A (ja) 2024-04-02
AU2012326370A1 (en) 2014-06-05
US20230172855A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
HUS1900047I1 (hu) Liofilizált liposzómák
ZA201307355B (en) Composite elements
ZA201306118B (en) Lyophilized formulations
PL2993263T3 (pl) Tkanina o bardzo wysokiej sprężystości
EP2691581A4 (en) joint assembly
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
EP2759709A4 (en) COMPRESSOR
GB201619994D0 (en) Improved fabric
GB2487250B (en) Compressor
GB201106391D0 (en) Novel composite
GB201106377D0 (en) Novel composite
GB201115014D0 (en) Peptides
GB201117700D0 (en) Improved fabric
PH32011000897S1 (en) Fabric
PH32011000883S1 (en) Fabric
PH32011000881S1 (en) Fabric
GB201113241D0 (en) Fabric dewrinkler
GB201114292D0 (en) Fabric
PH32011000888S1 (en) Fabric
PH32011000895S1 (en) Fabric
PH32011000894S1 (en) Fabric
PH32011000892S1 (en) Fabric
PH32011000891S1 (en) Fabric
PH32011000885S1 (en) Fabric